Marathon Petroleum Corp vs TG Therapeutics Inc — how do they compare? Marathon Petroleum Corp trades at $341.49 (market cap $94.48B), while TG Therapeutics Inc trades at $49.56 (market cap $7.64B). The key difference: Marathon Petroleum Corp is far larger — about 12.4× TG Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 1.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MPC | TGTX | |
|---|---|---|
Market Cap | $94.48B | $7.64B |
Sector | Energy | Health |
52-Week High | $336.42 | $59.06 |
52-Week Low | $159.11 | $26.94 |
Enterprise Value | $121.00B | $7.84B |
Dividend Yield | 1.19% | — |
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $342.47, up 6.91% with strong technical momentum and bullish analyst sentiment. The stock demonstrates robust fundamentals with Q2 2026 EPS of $17.73 beating estimates by 22.1%, supported by refining margin strength and disciplined operations. Valuation metrics remain attractive with P/E of 11.67 and EV/EBITDA of 6.87, while maintaining strong profitability with 47.9% ROE.
MPC presents a compelling investment case with projected revenue growth to $153.6B in 2026 and net profit margin expansion to 5.56%. Key risks include refining margin volatility and geopolitical impacts on energy markets. With 25 buy ratings and no sell recommendations, Wall Street consensus targets $332.70, though current price exceeds this level by 2.9%.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →